FINWIRES · TerminalLIVE
FINWIRES

$LH

10 stories mentioning LHUpdated just now

Every FINWIRES story that references LH, newest first.

Insider Trading

Labcorp Holdings Insider Sold Shares Worth $439,107, According to a Recent SEC Filing

Peter J Wilkinson, SVP, Chief Accounting Officer, on August 03, 2026, sold 1,420 shares in Labcorp Holdings (LH) for $439,107. Following the Form 4 filing with the SEC, Wilkinson has control over a total of 1,770 common shares of the company, with 1,770 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/920148/000092014826000172/xslF345X05/form4.xmlPrice: $313.47, Change: $+1.13, Percent Change: +0.36%

$LH
Wire

Barclays Raises Labcorp Price Target to $320 From $290, Maintains Equalweight Rating

Labcorp Holdings (LH) has an average rating of overweight and mean price target of $311.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $312.10, Change: $+4.95, Percent Change: +1.61%

$LH
Wire

Baird Adjusts Labcorp Price Target to $338 From $335, Maintains Outperform Rating

Labcorp (LH) has an average rating of overweight and mean price target of $311.19, according to analysts polled by FactSet.Price: $278.36, Change: $+1.55, Percent Change: +0.56%

$LH
Wire

Labcorp Holdings Insider Sold Shares Worth $1,502,314, According to a Recent SEC Filing

Adam H Schechter, Director, President and Chief Executive Officer, on May 11, 2026, sold 5,903 shares in Labcorp Holdings (LH) for $1,502,314. Following the Form 4 filing with the SEC, Schechter has control over a total of 107,234 common shares of the company, with 107,234 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/920148/000092014826000140/xslF345X05/form4.xmlPrice: $256.96, Change: $-0.39, Percent Change: -0.15%

$LH
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Labcorp Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $300 from $325, 16.6x our 2026 EPS estimate, a premium to LH's three-year historical forward average of 15.3x, supported by our favorable view for health care services, including healthy lab testing volume growth within an environment of high medical utilization, as well as attractive growth prospects given new therapies and aging demographics, in our opinion. We raise our 2026 EPS estimate to $18.03 from $17.90 and raise our 2027 estimate to $19.32 from $19.15. Q1 2026 acquisitions were $202 million, including operations from Crouse Health's Laboratory Alliance of Central New York, while management expressed confidence in the upcoming deal pipeline during the Q1 earnings conference call. Acquisitions totaled $582 million during 2025. LH anticipates a 30 bps headwind for diagnostics volumes in 2026 due to the recent expiration of ACA enhanced premium tax credits, which we expect to cause a meaningful drop in ACA exchange insurance coverage.

$LH
Wire

Leerink Partners Lowers Labcorp Price Target to $340 From $347

Labcorp (LH) has an average rating of overweight and mean price target of $311.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $257.19, Change: $+0.05, Percent Change: +0.02%

$LH
Research

Research Alert: Labcorp Holdings Q1: Testing Volumes, Central Labs Growth Lead To Eps Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LH reported Q1 adjusted EPS of $4.25, up 10.6% Y/Y and $0.13 above consensus, marking its 11th consecutive quarterly beat. Revenue increased 5.8% Y/Y to $3.54B with adjusted operating margin expanding 30 bps to 14.4%, supported by growth across both segments. Diagnostics Laboratories delivered consistent performance with 5.0% revenue growth to $2.76B, while Biopharma Laboratory Services grew 8.2% to $780.6M, supported by strong Central Labs performance. Management raised full-year guidance, increasing adjusted EPS midpoint by $0.13 to $18.03 and revenue growth expectations by 20 bps, reflecting confidence in the business trajectory. Cash flow generation showed notable improvement with FCF of $70.5M vs. negative $107.5M in the prior-year quarter. LH maintained balanced capital allocation, investing $202.2M in M&A while returning $159.2M to shareholders through buybacks and dividends. The $8.64B backlog with a 1.04 trailing-12-months book-to-bill ratio supports revenue visibility, in our view.

$LH
Research

Research Alert: Labcorp Holdings Q1: Testing Volumes, Central Labs Growth Lead To Eps Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:LH reported Q1 adjusted EPS of $4.25, up 10.6% Y/Y and $0.13 above consensus, marking its 11th consecutive quarterly beat. Revenue increased 5.8% Y/Y to $3.54B with adjusted operating margin expanding 30 bps to 14.4%, supported by growth across both segments. Diagnostics Laboratories delivered consistent performance with 5.0% revenue growth to $2.76B, while Biopharma Laboratory Services grew 8.2% to $780.6M, supported by strong Central Labs performance. Management raised full-year guidance, increasing adjusted EPS midpoint by $0.13 to $18.03 and revenue growth expectations by 20 bps, reflecting confidence in the business trajectory. Cash flow generation showed notable improvement with FCF of $70.5M vs. negative $107.5M in the prior-year quarter. LH maintained balanced capital allocation, investing $202.2M in M&A while returning $159.2M to shareholders through buybacks and dividends. The $8.64B backlog with a 1.04 trailing-12-months book-to-bill ratio supports revenue visibility, in our view.

$LH
Wire

Baird Adjusts Price Target on Labcorp Holdings to $332 From $327, Maintains Outperform Rating

Labcorp Holdings (LH) has an average rating of overweight and mean price target of $311.35, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $265.96, Change: $+1.63, Percent Change: +0.62%

$LH
Wire

Labcorp Partners With Children's Hospital of Philadelphia on Pediatric Diagnostics

Labcorp (LH) said Monday it is collaborating with the Children's Hospital of Philadelphia to develop and expand access to pediatric diagnostic tests across the US.Financial terms were not provided.The company said the agreement will combine its laboratory network with the hospital's research and clinical capabilities to support development and broader availability of new tests in areas including oncology, metabolic conditions and autoimmune disorders.Labcorp also said the collaboration is expected to establish a joint pipeline to identify and advance pediatric diagnostics and make them available nationally through its testing infrastructure.Price: $261.71, Change: $+0.76, Percent Change: +0.29%

$LH

Track with the FINWIRES app suite

FolioX
FolioX
Track LH in your portfolio
WheelAI
WheelAI
Analyze LH options with the wheel strategy
StockInsider
StockInsider
See market sentiment on LH